Selection and Efficacy-Influencing Factors of First-Line Biologic Agents in Moderate-to-Severe Ulcerative Colitis

NCT06962020 · clinicaltrials.gov ↗

RECRUITING

Status

400

Enrollment

OTHER

Sponsor class

Conditions

Ulcerative Colitis (UC)

Interventions

DRUG: first-line biologic：IFX
DRUG: first-line biologic:VDZ

Sponsor

Xijing Hospital of Digestive Diseases